Tanaka Y, et al. - Researchers assessed clinical outcomes during a phase III programme in patients who changed treatment from adalimumab to baricitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor. Study participants were randomised 3:3:2 to placebo, baricitinib 4 mg once daily, or adalimumab 40 mg biweekly in phase III RA-BEAM. Non-responders were rescued to open-label baricitinib 4 mg at week 16 or subsequent visits. Patients were able to enter a long-term extension at week 52 and continue baricitinib or switch from adalimumab to baricitinib 4 mg without adalimumab washout. Findings suggested an association of switching from adalimumab to baricitinib (without adalimumab washout) with improvements in disease control, physical function and pain during the initial 12 weeks postswitch, without an increase in treatment-emergent adverse events, serious adverse events or infections.